Axonics v. Medtronic: Federal Circuit Vacates & Remands Implantable Lead Patent Rulings
Axonics, Inc. challenged five Medtronic patents covering implantable cardiac and sacral nerve stimulation leads. After 518 days before the U.S. Court of Appeals for the Federal Circuit, the court vacated the underlying PTAB decisions and remanded all five patent matters for further proceedings.
Federal Circuit resets the board on five Medtronic implantable device patents
Axonics, Inc. appealed to the U.S. Court of Appeals for the Federal Circuit (Case No. 22-1451) against Medtronic, Inc., challenging PTAB patentability determinations concerning five patents: US8036756B2, US8626314B2, US4407303A, US5052407A, and US6055456A. The patents cover a range of implantable medical device technologies including cardiac electrode arrangements, lead fixation methods, tine-element leads, and a single and multi-polar implantable lead for sacral nerve electrical stimulation. The appeal was filed on February 7, 2022.
The Federal Circuit issued a verdict of 'VACATED AND REMANDED,' which is also recorded as the Basis of Termination. The court nullified the underlying PTAB decisions on patentability and returned the matters for further proceedings at the board level. The case closed on July 10, 2023. The specific grounds on which the court vacated each determination are not disclosed in the available public record.
The 518-day appellate timeline and the scope of the remand — spanning five patents across distinct implantable device technologies — suggest a substantively complex appeal. A vacatur and remand does not resolve the underlying validity questions; those questions return to the PTAB, meaning the competitive and freedom-to-operate consequences for both Axonics and Medtronic in the sacral neuromodulation and cardiac lead markets remain open.
See Complete Case & Patent Analysis →Filing to Vacated and Remanded in 518 days
518 days at the Federal Circuit — from filing Feb 2022 to close Jul 2023
US8036756B2 and four further implantable lead and stimulation patents
Any company developing implantable leads with tine fixation elements, sacral nerve stimulation systems, or cardiac electrode arrays should treat this five-patent cluster as a live FTO concern. The PTAB decisions that might have cleared these patents have been vacated. Until new board rulings are issued, the patents must be treated as presumptively valid and potentially enforceable against competing devices.
Official order — verbatim text
The Federal Circuit's 'VACATED AND REMANDED' disposition, mirrored in the recorded Basis of Termination, means the court found sufficient legal error in the PTAB's patentability determinations to nullify those decisions entirely rather than modify or affirm them. Under the appellate standard applied to PTAB decisions, the Federal Circuit reviews legal conclusions de novo and factual findings for substantial evidence; a vacatur on these grounds typically indicates a foundational error in the board's legal analysis or application of evidentiary standards, requiring reconsideration rather than a simple correction.
Federal Circuit vacates: what the remand means for both parties
What 'Vacated and Remanded' means at the Federal Circuit
A vacatur nullifies the lower tribunal's decision — here the PTAB's patentability rulings — as if it had not been made. Remand returns the matter to the PTAB to reconsider under corrected legal standards or findings. No final validity determination has been issued on any of the five patents. The proceedings effectively restart at the board level.
PTAB decisions nullifiedMedtronic's patents survive — but validity remains unresolved
Vacatur means the PTAB's prior rulings no longer stand. For Medtronic as patent holder, any adverse PTAB finding on any of the five patents has been wiped from the record. However, the patents have not been affirmatively confirmed as valid by the Federal Circuit; validity must be re-examined by the PTAB on remand, sustaining uncertainty for both parties.
Validity question remains openAxonics gets a second chance before the PTAB
Axonics, as appellant and the party that initiated the underlying IPR or validity challenges, benefits from the remand to the extent that PTAB findings unfavourable to it have also been reset. The corrected framework applied on remand may improve Axonics' position in the invalidity proceedings, though the outcome of those proceedings is not predetermined by the vacatur.
Remand restarts validity reviewSacral nerve and cardiac lead IP remains contested territory
With five patents — spanning sacral neuromodulation and cardiac lead fixation — returned to the PTAB, neither party has a clean competitive signal on enforceability. Companies designing around or licensing implantable lead technology should monitor the PTAB remand proceedings closely. Freedom-to-operate analysis on this portfolio cannot be finalised until new board decisions are issued.
FTO analysis remains prematureFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Axonics, Inc. | Company | /Search in Eureka ↗ |
| Defendant | Medtronic, Inc. | Company | /Search in Eureka ↗ |
| Plaintiff counsel | Aaron Matthew Nathan | Attorney | Counsel for Axonics, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Azra Hadzimehmedovic | Attorney | Counsel for Axonics, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Matthew D. Powers | Attorney | Counsel for Axonics, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Samantha A. Jameson | Attorney | Counsel for Axonics, Inc.Search in Eureka ↗ |
| Plaintiff counsel | William P. Nelson | Attorney | Counsel for Axonics, Inc.Search in Eureka ↗ |
| Plaintiff law firm | Tensegrity Law Group LLP | Law Firm | Representing Axonics, Inc.Search in Eureka ↗ |
| Defendant counsel | Chetan Bansal | Attorney | Counsel for Medtronic, Inc.Search in Eureka ↗ |
| Defendant counsel | Naveen Modi | Attorney | Counsel for Medtronic, Inc.Search in Eureka ↗ |
| Defendant counsel | Stephen Blake Kinnaird | Attorney | Counsel for Medtronic, Inc.Search in Eureka ↗ |
| Defendant law firm | Paul Hastings, LLP | Law Firm | Representing Medtronic, Inc.Search in Eureka ↗ |
| Presiding judge | Judge N/A | Judge | Court of Appeals for the Federal CircuitSearch in Eureka ↗ |
R&D signals in implantable lead and neuromodulation IP
Forward-looking patent intelligence on Axonics and Medtronic's filing activity and the competitive innovation landscape in sacral neuromodulation and implantable lead technology.
Axonics' expanding IP position in sacral neuromodulation
Axonics has built a commercial sacral neuromodulation business in direct competition with Medtronic's InterStim system. Tracking Axonics' patent filing activity in lead design, stimulation waveforms, and device miniaturisation reveals where the company is investing R&D resources and where it may be seeking to establish IP independence from Medtronic's foundational patents.
Axonics neuromodulation filingsFiling trends in tine-element lead fixation technology
Tine-based fixation for implantable leads is a crowded and actively developed area. Monitoring recent applications across Medtronic, Abbott, Boston Scientific, and smaller entrants reveals whether the field is shifting toward alternative fixation mechanisms — such as active fixation helix designs or bioresorbable anchors — that may offer design-around freedom relative to the patents at issue in this case.
Lead fixation innovation trendsMedtronic's cardiac and neuromodulation patent cluster depth
The five patents challenged in this case represent a subset of Medtronic's broader cardiac rhythm and neuromodulation IP estate. Analysing continuation families, related applications, and recently issued claims around US8036756B2 and US6055456A can reveal whether Medtronic has refreshed or extended coverage in ways that would survive an IPR even if the challenged patents are ultimately cancelled on remand.
Medtronic lead patent familiesAdjacent innovation space in multi-polar sacral stimulation leads
US6055456A claims a single and multi-polar implantable lead for sacral nerve stimulation — a configuration central to next-generation closed-loop neuromodulation systems. With this patent in PTAB remand limbo, the adjacent claim space around directional stimulation, sensing-enabled leads, and wireless power delivery for sacral applications may represent lower-encumbrance R&D territory worth mapping.
Sacral lead white spaceSimilar Federal Circuit appeals involving implantable medical device patent validity
Explore Federal Circuit appeals involving IPR patentability challenges to implantable cardiac and neuromodulation lead patents, including comparable Axonics and Medtronic proceedings.
What this case signals for the implantable medical device IP landscape
Five vacated PTAB decisions across sacral neuromodulation and cardiac lead patents send a clear signal: this technology domain remains actively contested at the highest appellate level.
Vacatur keeps five key Medtronic patents in legal limbo
Until the PTAB issues new decisions on remand, the validity status of US8036756B2, US8626314B2, US4407303A, US5052407A, and US6055456A is unresolved. Any product or design-around strategy that assumed a particular PTAB outcome must be re-evaluated against the reset proceedings.
Sacral neuromodulation IP is a high-stakes competitive battleground
The inclusion of the sacral nerve stimulation lead patent (US6055456A) alongside four cardiac lead patents signals that Medtronic's neuromodulation IP portfolio faces sustained challenge from Axonics, a direct commercial rival. Companies entering or expanding in this space should treat the PTAB remand docket as a live risk register.
Axonics v Medtronic — key questions answered
The Federal Circuit issued a 'VACATED AND REMANDED' decision, nullifying the underlying PTAB patentability determinations on all five patents at issue and returning the matters to the PTAB for further proceedings. The case closed July 10, 2023. No final validity determination was issued by the Federal Circuit.
Five Medtronic patents were at issue: US8036756B2 (implantable lead with tine elements), US8626314B2 (sacral nerve stimulation lead), US4407303A (cardiac spiral patch electrode), US5052407A (endocardial electrode arrangement), and US6055456A (single and multi-polar sacral stimulation lead).
Vacatur means the PTAB's prior decisions are nullified and carry no legal weight. The patents are not confirmed valid, but any adverse PTAB finding has also been wiped. Validity of all five patents must be reconsidered by the PTAB under the corrected framework directed by the Federal Circuit. The patents remain presumptively valid in the interim.
US6055456A covers a single and multi-polar implantable lead for sacral nerve electrical stimulation — core technology in Medtronic's InterStim sacral neuromodulation system, which competes directly with Axonics' commercial product. The unresolved validity of this patent sustains freedom-to-operate uncertainty for Axonics and enforceability uncertainty for Medtronic.
Companies developing implantable leads, sacral neuromodulation systems, or cardiac electrode arrays should treat all five patents as presumptively valid pending new PTAB decisions. A current FTO analysis mapped to each patent's claim scope — including any continuations or related applications — is advisable before finalising product designs or entering the market with competing devices.
This page is compiled from public court dockets and third-party patent and litigation data via PatSnap Eureka, and is provided for general informational purposes only. The information shown — including party names, patent and application numbers, dates, case status, outcomes, and any analysis — may be incomplete, may not reflect the most recent filings or legal status, and may contain errors or omissions. Verify all details against official court records (for example, PACER) and the relevant patent office before relying on them.
Nothing on this page constitutes legal advice or a legal opinion on the validity, infringement, enforceability, or scope of any patent or case, and no attorney‑client relationship is created by its use. Any description of an outcome (such as a dismissal, settlement, or consent judgment) is a general summary, not a legal determination. All patents, trademarks, and company or law‑firm names are the property of their respective owners. PatSnap makes no warranty as to the accuracy or completeness of this content and disclaims, to the fullest extent permitted by law, all liability for reliance on it. For advice on a specific matter, consult qualified legal counsel.
PatSnap Eureka searches patents and litigation data to answer instantly.